ALMASIO, Pier Luigi
 Distribuzione geografica
Continente #
NA - Nord America 9.847
EU - Europa 3.175
AS - Asia 858
AF - Africa 12
OC - Oceania 7
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.910
Nazione #
US - Stati Uniti d'America 9.829
IT - Italia 967
CN - Cina 692
UA - Ucraina 518
FI - Finlandia 473
IE - Irlanda 291
GB - Regno Unito 222
DE - Germania 216
SE - Svezia 122
RU - Federazione Russa 107
BE - Belgio 90
RO - Romania 54
KR - Corea 50
FR - Francia 48
TR - Turchia 29
IN - India 26
HK - Hong Kong 19
AT - Austria 13
IR - Iran 13
CA - Canada 11
CH - Svizzera 9
EG - Egitto 9
JP - Giappone 9
BG - Bulgaria 8
GR - Grecia 8
NL - Olanda 8
MX - Messico 7
AU - Australia 6
BR - Brasile 6
LB - Libano 6
CZ - Repubblica Ceca 5
DK - Danimarca 4
EU - Europa 4
PL - Polonia 4
HR - Croazia 3
UZ - Uzbekistan 3
CI - Costa d'Avorio 2
ES - Italia 2
PK - Pakistan 2
SY - Repubblica araba siriana 2
BD - Bangladesh 1
HU - Ungheria 1
ID - Indonesia 1
MC - Monaco 1
MD - Moldavia 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PE - Perù 1
SA - Arabia Saudita 1
SG - Singapore 1
TW - Taiwan 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 13.910
Città #
Fairfield 1.699
Woodbridge 936
Houston 899
Ashburn 891
Chandler 659
Wilmington 650
Seattle 646
Cambridge 584
Ann Arbor 438
Dublin 290
Jacksonville 277
Medford 217
Palermo 215
Des Moines 152
Nanjing 145
Altamura 137
Princeton 135
Lawrence 117
San Diego 101
Milan 93
Brussels 90
Dearborn 82
Tulsa 76
Boardman 73
Shenyang 61
Beijing 59
Jinan 57
Nanchang 54
Changsha 45
London 45
Ludwigshafen am Rhein 43
New York 43
Seongnam 40
Hebei 38
Jiaxing 34
San Paolo di Civitate 31
Tianjin 30
Izmir 29
Venice 28
Ningbo 27
Saint Petersburg 27
Phoenix 25
Falls Church 22
Auburn Hills 18
Lanzhou 18
San Mateo 17
Taiyuan 17
Zhengzhou 17
Verona 15
Guangzhou 14
Kumar 14
Bremen 13
Central 13
Hangzhou 13
Washington 13
Boydton 12
Haikou 12
Norwalk 11
Los Angeles 10
Taizhou 10
Tehran 10
Chicago 9
Rome 9
Tappahannock 9
Bari 7
Helsinki 7
Chiswick 6
Kilburn 6
Kunming 6
Pune 6
Wandsworth 6
Central District 5
Frankfurt Am Main 5
Hounslow 5
Moscow 5
Orange 5
Ottawa 5
Augusta 4
Brno 4
Changchun 4
Foggia 4
Mumbai 4
Munich 4
Prescot 4
Redwood City 4
Vienna 4
Aachen 3
Agrigento 3
Amsterdam 3
Atlanta 3
Columbus 3
Detroit 3
Hanover 3
Islington 3
Lauro 3
Messina 3
Naples 3
Rio Saliceto 3
Seoul 3
São Paulo 3
Totale 10.766
Nome #
The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. 327
HCV genotypes in Sicily: is there any evidence of a shift? 232
Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. 179
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 179
Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol 177
Clinical course and management of acute and chronic viral hepatitis during pregnancy. 173
Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study*. 164
Clinical course and genetic susceptibility of primary biliary cirrhosis: Analysis of a prospective cohort 161
Esophageal motility changes after thyroidectomy: possible associations with postoperative voice and swallowing disorders 158
The aetiology of chronic hepatitis in Italy: results from a multicentre national study 157
Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction 157
Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. 155
A functional study of the esophagus in patients with non-cardiac chest pain and dysphagia 155
Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis 152
Long-term manometric study of anal sphincter function after hemorrhoidectomy. 151
Botulinum toxin vs. topical glyceryl trinitrate ointment for pain control in patients undergoing hemorrhoidectomy: a randomized trial. 150
Impact of hepatitis C virus infection on lifestyle. 150
Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b 149
Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. 147
Pharmacological Treatment of Patients with Chronic Critical Limb Ischemia: L-Propionyl-Carnitine Enhances the Short-Term Effects of PGE-1 147
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology 146
Improvement of wound healing after hemorrhoidectomy: a double-blind, randomized study of botulinum toxin injection 145
Kinetic analysis of insulin resistance and serum adipocytokines levels during peginterferon alpha-2A plus ribavirin therapy in non-diabetic HCV patients 141
Management of hepatitis B virus infection in the underprivileged world. 140
STAGING OF FIBROSIS BY LIVER STIFFNESS MEASUREMENT IN THALASSEMICS WITH IRON OVERLOAD 139
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial 139
Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. 139
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 139
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 138
B lymphocyte intestinal homing in inflammatory bowel disease. 138
Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. 137
STORIA NATURALE DELLA CIRROSI EPATICA 136
Granular cell tumor of stomach: a case report and review of literature. 136
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. 136
Characteristics of liver cirrhosis in Italy: results from a multicenter national study 135
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 134
Interaction of alcohol intake and cofactors on the risk of cirrhosis. 133
PROSPECTIVE, RANDOMIZED, CROSSOVER COMPARISON OF SUBLINGUAL APOMORPHINE (3 mg) WITH ORAL SILDENAFIL (50 mg) FOR MALE ERECTILE DYSFUNCTION 132
Esophageal motility changes after thyroidectomy; possible associations with postoperative voice and swallowing disorders: preliminary results. 130
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 129
Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. 128
Current practice of hepatitis C treatment in Southern Italy. 128
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 128
Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy 127
Chronic hepatitis B in Italy: new features of an old disease--approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. 126
HCV infection is a risk factor for gallstone disease in liver cirrhosis: an Italian epidemiological survey. 125
Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases 123
Liver disease in chelated transfusion-dependent thalassemics: the role of iron and chronic hepatitis C 122
Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases 122
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. 121
Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects 120
Impact of comorbidities on the severity of chronic hepatitis B at presentation. 120
Unusual B cell morphology in inflammatory bowel disease. 119
Small bowel angiodysplasia associated with von Willebrand's disease: report of a case 117
Weight-based dosing: which impact on efficacy and safety of therapy? 115
Trends of aetiological factors of hepatocellular carcinoma in Italy 115
The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study 115
The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases 115
Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy. 113
Necrotizing Soft Tissue Fasciitis after Intramuscular Injection 112
New therapeutic prospects in HCV treatment. 111
Chronic hepatitis C infection and insulin resistance: two best friends. 110
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. 109
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study 108
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. 108
Treating chronic hepatitis C in daily practice with PEG-IFN alfa2B and ribavirin. An Italian multicentre study 107
Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases 107
Liver function test abnormalities in patients with inflammatory bowel diseases: A hospital-based survey 106
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. 105
Experts' opinions on the role of liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.) 104
Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy 104
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. 103
Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome 103
Inguinal hernioplasty improves the quality of life in patients with cirrhosis. 103
Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). 103
Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. 102
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies 101
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 101
HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy 100
null 100
Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis 100
Geographical pattern of chronic liver diseases in Italy: Results from two pooled national surveys 99
The aetiological pattern of hepatocellular carcinoma ( HCC) in Italy is changing 98
Current practice of chronic hepatitis B treatment in Southern Italy. 97
Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction 96
Morphological distribution of μ chains and cd15 receptors in colorectal polyp and adenocarcinoma specimens. 95
The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy 93
Epidemiology and clinical course of drug-induced liver injury 92
CLINICAL COURSE OF NIMESULIDE-INDUCED LIVER INJURY 91
HALT-C in the final analysis: a molehill out of a mountain. 91
HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial. 91
Hepatitis delta infection in Italian patients: towards the end of the story? 90
Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. 87
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication 86
Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study. 85
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. 83
IL-10 and TNF-α polymorphisms and the recovery from HCV infection 83
The impact of sustained virological response on clinical outcome in compensated HCV cirrhosis: a prospective cohort study 82
Influence of liver disease staging on sustained virological response in HCV “Favourable” genotypes treated with PEG-interferon and ribavirin: Data from clinical practice 76
Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study 74
Totale 12.457
Categoria #
all - tutte 46.845
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.845


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.127 0 0 0 0 0 0 0 0 75 185 452 415
2019/20204.514 480 204 299 481 525 549 423 295 429 181 527 121
2020/20212.076 128 172 275 160 217 86 158 128 214 161 175 202
2021/20221.637 70 379 35 50 54 71 104 72 216 195 120 271
2022/20232.082 214 416 31 201 256 316 126 144 227 16 75 60
2023/2024707 62 124 65 52 65 156 84 37 62 0 0 0
Totale 14.419